Impel Pharmaceuticals reports Q4 adjusted EPS (97c), consesnus ($1.11)

Reports Q4 revenue $5M, consensus $4.97M. "We continued to see strong growth in Trudhesa prescriptions as we moved into 2023. The Company’s priority objective is to maximize the growth potential of Trudhesa in a market where we already hold 4.3 percent of total branded acute migraine prescriptions among Trudhesa prescribers," said Adrian Adams, Chairman of the Board and CEO. "Additionally, we continue to see increased productivity and efficiency from the field force expansion we completed in July 2022. This, together with the increased number of prescriptions reimbursed and resultant positive impact on revenue growth, points to the value creation opportunity with Impel."